MARKET

AMTI

AMTI

Applied Molecular Transport Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.24
-0.84
-2.27%
Closed 16:00 01/21 EST
OPEN
37.11
PREV CLOSE
37.08
HIGH
37.82
LOW
35.73
VOLUME
49.63K
TURNOVER
--
52 WEEK HIGH
37.88
52 WEEK LOW
17.05
MARKET CAP
1.14B
P/E (TTM)
-25.2931
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
*DJ Applied Molecular: Rich Recently Served as Senior Vice Pres, Ops at UNITY Biotechnology >AMTI
Dow Jones · 3d ago
Applied Molecular Transport Appoints Douglas Rich as Chief Technical Officer
GlobeNewswire · 3d ago
We Think Applied Molecular Transport (NASDAQ:AMTI) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 12/05/2020 06:24
We Think Applied Molecular Transport (NASDAQ:AMTI) Can Afford To Drive Business Growth
Simply Wall St. · 12/05/2020 06:24
Applied Molecular Transport to Present at Evercore ISI 3rd Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:30 p.m. ET. A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.About Applied Molecular Transport Inc.Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly tablet and capsule forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.Investor Relations Contact: Andrew Chang Head, Investor Relations & Corporate Communications achang@appliedmt.comMedia Contacts: Alexandra Santos Wheelhouse Life Science Advisors asantos@wheelhouselsa.comAljanae Reynolds Wheelhouse Life Science Advisors areynolds@wheelhouselsa.com
GlobeNewswire · 11/24/2020 13:00
Applied Molecular Transport to Present at Evercore ISI 3rd Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will partic...
GlobeNewswire · 11/24/2020 13:00
Applied Molecular Transport reports Q3 results
Applied Molecular Transport (AMTI): Q3 GAAP EPS of -$0.48.Cash, cash equivalents, and investments of $147.3MPress Release
Seekingalpha · 11/12/2020 21:41
Applied Molecular Q3 EPS $(0.48) Up From $(1.07) YoY
Applied Molecular (NASDAQ:AMTI) reported quarterly losses of $(0.48) per share. This is a 55.14 percent increase over losses of $(1.07) per share from the same period last year.
Benzinga · 11/12/2020 21:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMTI. Analyze the recent business situations of Applied Molecular Transport Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMTI stock price target is 34.67 with a high estimate of 38.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 18.14M
% Owned: 57.75%
Shares Outstanding: 31.40M
TypeInstitutionsShares
Increased
7
2.46M
New
42
-1.08M
Decreased
2
299.53K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/Independent Director
Helen Kim
Chief Executive Officer/Co-Founder/Director
Tahir Mahmood
Co-Founder/Chief Scientific Officer/Director
Randall Mrsny
Chief Financial Officer
Shawn Cross
Senior Vice President
Chuck Olson
Chief Technology Officer
Douglas Rich
Vice President
Derek Maclean
Vice President
Andy Whitney
Other
Elizabeth Bhatt
Other
Bittoo Kanwar
Independent Director
Graham Cooper
Independent Director
David Lamond
Independent Director
Aaron VanDevender
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform including its product candidate, AMT-101, an oral GI-selective rhIL-10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of rhIL-22. The Company’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics, with development-stage drugs.
More

Webull offers kinds of Applied Molecular Transport Inc. stock information, including NASDAQ:AMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMTI stock methods without spending real money on the virtual paper trading platform.